

# PROVIDER QUICK POINTS

## PROVIDER INFORMATION



October 11, 2023

### Commercial Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Izervay™, and Veopoz™

Effective **October 11, 2023**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug Names
Beyfortus™ (nirsevimab-alip) solution for subcutaneous (SC) injection
Daxxify® (daxibotulinumtoxinA-lanm) lyophilized powder for reconstitution and intramuscular (IM) injection
Izervay™ (avacincaptad pegol) solution for intravitreal (IVI) injection
Veopoz™ (pozelimab-bbfg) solution for intravenous (IV) or subcutaneous (SC) administration

#### Products Impacted

These exclusions apply to commercial lines of business.

#### Questions?

Please contact provider services at **(651) 662-5200** or **1-800-262-0820**.